曲妥珠单抗联合化疗治疗HER2阳性乳腺癌的效果及对免疫功能的影响

打开文本图片集

Effect of Trastuzumab Combined with Chemotherapy on HER2 Positive Breast Cancer and Its Influenceon Immune Function/YUANYingxia，NIE Yuqian，MUHuaiwei.//Medical Innovationof China， 2025，22（25）： 125-129

[Abstract] Objective：To evaluate the therapeutic efects of combining Trastuzumab with chemotherapy for patients diagnosed with human epidermal growth factor receptor 2 （HER2） positive breast cancer.Method： Ninety HER2 positivebreast cancer patients admitted to Hebei Yizhou Cancer Hospital from January 2O22 to July 2023 were selected as the study subjects.The patients were randomly divided into an observation group （ n =45）and a control group （n=45）using a random number table method.The control group received neoadjuvant chemotherapy，while the observation group received neoadjuvant chemotherapy plus Trastuzumab-targeted therapy.Both groups were treated forthree cycles.Thetherapeuticeficacy，HER2andcarbohydrateantigen153（CA153）levels，Tlymphocyte levels， and adverse reactions were compared between the two groups.Result： After three courses of treatment，there was a statistically significant difference in the therapeutic effect between the two groups （ P <0.05）; the total remission rate of the observation group was higher than that of the control group （ P <0.05）.After three courses of treatment， levels of HER2 and CA153 in observation group were lower than those in the control group （ P <0.05）.After three courses of treatment， the observation group exhibited significantly elevated levels of CD 3+ ，CD 4+ ，and CD4+/CD8 †+ compared to the control group （ P <0.05）.There wereno statistically significant differencesin the adverse reactions between the two groups （P>O.O5）.Conclusion： Trastuzumab combined with chemotherapy is effective in the treatmentof HER2 positive breast cancer， specific mechanism involves the regulation immune function.

[Keywords] Breast cancerHuman epidermal growth factor receptor 2 positiveTrastuzumab ChemotherapyImmune function

First-author's address：Oncology Department，Hebei Yizhou Cancer Hospital，Zhuozhou 072750 China

doi：10.3969/j.issn.1674-4985.2025.25.029

人表皮生长因子受体2（humanepidermalgrowthfactorreceptor2，HER2）是与乳腺癌关系最为密切的基因，也是临床乳腺癌治疗预后监测的重要基因，同时常被汇总了靶向药物选择用于基本的治疗[-2]乳腺癌患者HER2阳性与否可能对化疗、内分泌治疗的疗效产生一定影响，约有 25% 乳腺癌患者存在HER2阳性，表现出更强的致病性、治疗预后更差[3-4]。（剩余5340字）